Vaccinex Inc Financials
This page shows Vaccinex Inc (VCNX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Vaccinex Inc generated $601K in revenue in fiscal year 2024. This represents an increase of 5.4% from the prior year.
Vaccinex Inc's EBITDA was -$18.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 18.1% from the prior year.
Vaccinex Inc generated -$16.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 24.4% from the prior year.
Vaccinex Inc reported -$18.6M in net income in fiscal year 2024. This represents an increase of 8.0% from the prior year.
Vaccinex Inc earned $-8.88 per diluted share (EPS) in fiscal year 2024. This represents an increase of 79.7% from the prior year.
Vaccinex Inc held $1.1M in cash against $0 in long-term debt as of fiscal year 2024.
Vaccinex Inc had 3M shares outstanding in fiscal year 2024. This represents an increase of 199.9% from the prior year.
Vaccinex Inc's operating margin was -3117.3% in fiscal year 2024, reflecting core business profitability. This is up 897.6 percentage points from the prior year.
Vaccinex Inc's net profit margin was -3100.5% in fiscal year 2024, showing the share of revenue converted to profit. This is up 452.3 percentage points from the prior year.
Vaccinex Inc invested $12.5M in research and development in fiscal year 2024. This represents a decrease of 24.3% from the prior year.
Vaccinex Inc invested $22K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 67.2% from the prior year.
VCNX Income Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'24 | Q3'24 | Q3'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $213K+309.6% | $52K-77.6% | $232K+123.1% | $104K | N/A | $20K | N/A | $550K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.1M-32.6% | $3.2M-18.1% | $3.9M+14.2% | $3.4M | N/A | $4.4M-13.8% | $5.0M+32.5% | $3.8M |
| SG&A Expenses | $1.5M+1.9% | $1.4M-31.1% | $2.1M+16.4% | $1.8M | N/A | $1.5M-26.0% | $2.0M+17.6% | $1.7M |
| Operating Income | -$3.4M+25.6% | -$4.6M+20.4% | -$5.7M-12.8% | -$5.1M | N/A | -$5.8M+17.6% | -$7.1M-41.9% | -$5.0M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 |
| Income Tax | $0 | $0 | $0 | $0 | N/A | $0 | $0 | $0 |
| Net Income | -$3.4M+41.1% | -$5.7M-1.8% | -$5.6M-44.5% | -$3.9M | N/A | -$4.9M+30.4% | -$7.1M-42.3% | -$5.0M |
| EPS (Diluted) | $-0.01+99.6% | $-2.83+8.7% | $-3.10-5.4% | $-2.94 | N/A | $-15.25+37.9% | $-24.54-17.5% | $-20.89 |
VCNX Balance Sheet
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'24 | Q3'24 | Q3'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.6M-46.5% | $4.9M+105.1% | $2.4M-67.9% | $7.4M+102.9% | $3.6M+41.9% | $2.6M-17.1% | $3.1M-37.0% | $4.9M |
| Current Assets | $2.5M-46.8% | $4.8M+116.0% | $2.2M-69.2% | $7.2M+113.6% | $3.3M+51.8% | $2.2M-17.7% | $2.7M-39.4% | $4.4M |
| Cash & Equivalents | $1.1M-61.9% | $2.9M+1147.2% | $233K-92.2% | $3.0M+93.6% | $1.5M+1108.7% | $127K-93.3% | $1.9M-42.6% | $3.3M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $838K-14.9% | $985K-5.7% | $1.0M-62.3% | $2.8M+188.8% | $961K+3.0% | $933K+8381.8% | $11K | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $5.1M-17.7% | $6.2M+18.0% | $5.2M+11.0% | $4.7M-20.7% | $5.9M-7.5% | $6.4M+83.2% | $3.5M+40.6% | $2.5M |
| Current Liabilities | $5.1M-17.7% | $6.2M+18.0% | $5.2M+11.2% | $4.7M-20.5% | $5.9M-7.0% | $6.4M+88.1% | $3.4M+46.5% | $2.3M |
| Long-Term Debt | $0 | N/A | N/A | $6K-76.9% | $26K-40.9% | $44K-30.2% | $63K-23.2% | $82K |
| Total Equity | -$2.5M-88.3% | -$1.3M+53.9% | -$2.9M-207.9% | $2.7M+214.9% | -$2.3M+40.3% | -$3.9M-814.7% | -$423K-117.6% | $2.4M |
| Retained Earnings | -$358.6M-0.9% | -$355.2M-1.6% | -$349.5M-1.6% | -$343.8M-1.1% | -$339.9M-1.0% | -$336.6M-1.5% | -$331.7M-2.2% | -$324.6M |
VCNX Cash Flow Statement
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'24 | Q3'24 | Q3'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | N/A | -$4.6M | N/A | N/A | N/A | -$5.0M |
| Capital Expenditures | N/A | N/A | N/A | $0 | N/A | N/A | N/A | $49K |
| Free Cash Flow | N/A | N/A | N/A | -$4.6M | N/A | N/A | N/A | -$5.1M |
| Investing Cash Flow | N/A | N/A | N/A | $0 | N/A | N/A | N/A | -$49K |
| Financing Cash Flow | N/A | N/A | N/A | $6.1M | N/A | N/A | N/A | $2.0M |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VCNX Financial Ratios
| Metric | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'24 | Q3'24 | Q3'24 | Q1'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1590.1%+7163.7pp | -8753.9%-6287.5pp | -2466.4%+2412.5pp | -4878.9% | N/A | -29170.0% | N/A | -906.5% |
| Net Margin | -1584.0%+9439.0pp | -11023.1%-8595.9pp | -2427.2%+1320.0pp | -3747.1% | N/A | -24560.0% | N/A | -902.2% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -130.0%-11.9pp | -118.1%+119.8pp | -237.9%-185.0pp | -52.9% | N/A | -192.0%+36.8pp | -228.8%-127.5pp | -101.4% |
| Current Ratio | 0.50-0.3 | 0.77+0.3 | 0.42-1.1 | 1.52+1.0 | 0.57+0.2 | 0.35-0.4 | 0.79-1.1 | 1.91 |
| Debt-to-Equity | 0.00+4.7 | -4.67-2.8 | -1.83-1.8 | 0.00+0.0 | -0.010.0 | -0.01+0.1 | -0.15-0.2 | 0.03 |
| FCF Margin | N/A | N/A | N/A | -4453.9% | N/A | N/A | N/A | -925.3% |
Note: Shareholder equity is negative (-$2.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.50), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks.
Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.
Operating cash flow vs net income. Above 1.0x = cash-backed earnings.
Operating income vs interest expense. Above 5x = safe, below 2x = risky.
Similar Companies
Frequently Asked Questions
What is Vaccinex Inc's annual revenue?
Vaccinex Inc (VCNX) reported $601K in total revenue for fiscal year 2024. This represents a 5.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Vaccinex Inc's revenue growing?
Vaccinex Inc (VCNX) revenue grew by 5.4% year-over-year, from $570K to $601K in fiscal year 2024.
Is Vaccinex Inc profitable?
No, Vaccinex Inc (VCNX) reported a net income of -$18.6M in fiscal year 2024, with a net profit margin of -3100.5%.
What is Vaccinex Inc's earnings per share (EPS)?
Vaccinex Inc (VCNX) reported diluted earnings per share of $-8.88 for fiscal year 2024. This represents a 79.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Vaccinex Inc's EBITDA?
Vaccinex Inc (VCNX) had EBITDA of -$18.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Vaccinex Inc have?
As of fiscal year 2024, Vaccinex Inc (VCNX) had $1.1M in cash and equivalents against $0 in long-term debt.
What is Vaccinex Inc's operating margin?
Vaccinex Inc (VCNX) had an operating margin of -3117.3% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Vaccinex Inc's net profit margin?
Vaccinex Inc (VCNX) had a net profit margin of -3100.5% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Vaccinex Inc's free cash flow?
Vaccinex Inc (VCNX) generated -$16.2M in free cash flow during fiscal year 2024. This represents a 24.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Vaccinex Inc's operating cash flow?
Vaccinex Inc (VCNX) generated -$16.2M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Vaccinex Inc's total assets?
Vaccinex Inc (VCNX) had $2.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Vaccinex Inc's capital expenditures?
Vaccinex Inc (VCNX) invested $22K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Vaccinex Inc spend on research and development?
Vaccinex Inc (VCNX) invested $12.5M in research and development during fiscal year 2024.
How many shares does Vaccinex Inc have outstanding?
Vaccinex Inc (VCNX) had 3M shares outstanding as of fiscal year 2024.
What is Vaccinex Inc's current ratio?
Vaccinex Inc (VCNX) had a current ratio of 0.50 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Vaccinex Inc's debt-to-equity ratio?
Vaccinex Inc (VCNX) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Vaccinex Inc's return on assets (ROA)?
Vaccinex Inc (VCNX) had a return on assets of -717.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Vaccinex Inc's cash runway?
Based on fiscal year 2024 data, Vaccinex Inc (VCNX) had $1.1M in cash against an annual operating cash burn of $16.2M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Vaccinex Inc's debt-to-equity ratio negative or unusual?
Vaccinex Inc (VCNX) has negative shareholder equity of -$2.5M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Vaccinex Inc's Piotroski F-Score?
Vaccinex Inc (VCNX) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.
Are Vaccinex Inc's earnings high quality?
Vaccinex Inc (VCNX) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.
Can Vaccinex Inc cover its interest payments?
Vaccinex Inc (VCNX) has an interest coverage ratio of -9367.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline.
How financially healthy is Vaccinex Inc?
Vaccinex Inc (VCNX) scores 11 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks.